CAMX 2025 showcased the power of collaboration and purposeful innovation, a clear reminder that the composites industry is all about human potential.
VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback